Recombinant allergens for immunotherapy
Recombinant allergens can be produced as defined molecules in consistent quality and unlimited amounts according to the corresponding DNA template. Furthermore, they can be modified to reduce their allergenic activity and to foster certain advantageous immunologic properties. Recombinant allergens e...
Gespeichert in:
| Veröffentlicht in: | Journal of allergy and clinical immunology 2007-04, Vol.119 (4), p.826-830 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 830 |
|---|---|
| container_issue | 4 |
| container_start_page | 826 |
| container_title | Journal of allergy and clinical immunology |
| container_volume | 119 |
| creator | Valenta, Rudolf, MD Niederberger, Verena, MD |
| description | Recombinant allergens can be produced as defined molecules in consistent quality and unlimited amounts according to the corresponding DNA template. Furthermore, they can be modified to reduce their allergenic activity and to foster certain advantageous immunologic properties. Recombinant allergens equaling the natural allergens are available for diagnostic and therapeutic purposes, and modified versions have been developed with the aim to to reduce IgE-mediated side effects during immunotherapy. First injection immunotherapy trials conducted with recombinant vaccines for birch pollen and grass pollen allergy show that recombinant allergen–based immunotherapy has vaccination characteristics and is clinically effective. The obtained results hold promise that recombinant allergen–based immunotherapy will improve current immunotherapy practice and may open possibilities for new treatment strategies and possibly even for prophylactic vaccination. |
| doi_str_mv | 10.1016/j.jaci.2007.01.025 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70357332</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091674907002345</els_id><sourcerecordid>3239136001</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-83af5ccfb5dbe0a10e4692dcde8c9b534b09ff3f8f212ea6719b12462cef598a3</originalsourceid><addsrcrecordid>eNp9kV2r1DAQhoMonvXoH_BCFkS9ap0kTZOACHLwCw4IflyHNJ1oapuuSSvsvzdlFxbOhVdh4HknM88Q8pRCTYG2r4d6sC7UDEDWQGtg4h7ZUdCyahUT98kOQNOqlY2-Io9yHqDUXOmH5IpKzoVS7Y68-opunroQbVz2dhwx_cSY935O-zBNa5yXX5js4fiYPPB2zPjk_F6THx_ef7_5VN1--fj55t1t5ZpWLpXi1gvnfCf6DsFSwKbVrHc9Kqc7wZsOtPfcK88oQ9tKqjvKmpY59EIry6_Jy1PfQ5r_rJgXM4XscBxtxHnNRgIXZXhWwOd3wGFeUyyzGSqgkW3ZsCkUO1EuzTkn9OaQwmTT0VAwm0QzmE2i2SQaoKZILKFn59ZrN2F_iZytFeDFGbDZ2dEnG13IF05JCpyqwr05cViM_Q2YTHYBo8M-JHSL6efw_zne3om7McRQfvyNR8yXfU1mBsy37dzbtUECMN4I_g9p-qNt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1504763354</pqid></control><display><type>article</type><title>Recombinant allergens for immunotherapy</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Valenta, Rudolf, MD ; Niederberger, Verena, MD</creator><creatorcontrib>Valenta, Rudolf, MD ; Niederberger, Verena, MD</creatorcontrib><description>Recombinant allergens can be produced as defined molecules in consistent quality and unlimited amounts according to the corresponding DNA template. Furthermore, they can be modified to reduce their allergenic activity and to foster certain advantageous immunologic properties. Recombinant allergens equaling the natural allergens are available for diagnostic and therapeutic purposes, and modified versions have been developed with the aim to to reduce IgE-mediated side effects during immunotherapy. First injection immunotherapy trials conducted with recombinant vaccines for birch pollen and grass pollen allergy show that recombinant allergen–based immunotherapy has vaccination characteristics and is clinically effective. The obtained results hold promise that recombinant allergen–based immunotherapy will improve current immunotherapy practice and may open possibilities for new treatment strategies and possibly even for prophylactic vaccination.</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2007.01.025</identifier><identifier>PMID: 17335886</identifier><identifier>CODEN: JACIBY</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Allergens - adverse effects ; Allergens - genetics ; Allergens - therapeutic use ; Allergies ; Allergy and Immunology ; Animals ; Biological activity ; Biological and medical sciences ; Competition ; Deoxyribonucleic acid ; Derivatives ; Desensitization, Immunologic - methods ; Desensitization, Immunologic - trends ; DNA ; Experiments ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Humans ; Immunopathology ; immunotherapy ; Medical sciences ; Patients ; Pollen ; Pollen - adverse effects ; Pollen - immunology ; Quality standards ; Recombinant allergens ; Recombinant Proteins - genetics ; Recombinant Proteins - immunology ; Recombinant Proteins - therapeutic use ; Studies ; Vaccines ; Vaccines, Synthetic - genetics ; Vaccines, Synthetic - immunology ; Vaccines, Synthetic - therapeutic use</subject><ispartof>Journal of allergy and clinical immunology, 2007-04, Vol.119 (4), p.826-830</ispartof><rights>American Academy of Allergy, Asthma & Immunology</rights><rights>2007 American Academy of Allergy, Asthma & Immunology</rights><rights>2007 INIST-CNRS</rights><rights>Copyright Elsevier Limited Apr 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-83af5ccfb5dbe0a10e4692dcde8c9b534b09ff3f8f212ea6719b12462cef598a3</citedby><cites>FETCH-LOGICAL-c467t-83af5ccfb5dbe0a10e4692dcde8c9b534b09ff3f8f212ea6719b12462cef598a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jaci.2007.01.025$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18710318$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17335886$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Valenta, Rudolf, MD</creatorcontrib><creatorcontrib>Niederberger, Verena, MD</creatorcontrib><title>Recombinant allergens for immunotherapy</title><title>Journal of allergy and clinical immunology</title><addtitle>J Allergy Clin Immunol</addtitle><description>Recombinant allergens can be produced as defined molecules in consistent quality and unlimited amounts according to the corresponding DNA template. Furthermore, they can be modified to reduce their allergenic activity and to foster certain advantageous immunologic properties. Recombinant allergens equaling the natural allergens are available for diagnostic and therapeutic purposes, and modified versions have been developed with the aim to to reduce IgE-mediated side effects during immunotherapy. First injection immunotherapy trials conducted with recombinant vaccines for birch pollen and grass pollen allergy show that recombinant allergen–based immunotherapy has vaccination characteristics and is clinically effective. The obtained results hold promise that recombinant allergen–based immunotherapy will improve current immunotherapy practice and may open possibilities for new treatment strategies and possibly even for prophylactic vaccination.</description><subject>Allergens - adverse effects</subject><subject>Allergens - genetics</subject><subject>Allergens - therapeutic use</subject><subject>Allergies</subject><subject>Allergy and Immunology</subject><subject>Animals</subject><subject>Biological activity</subject><subject>Biological and medical sciences</subject><subject>Competition</subject><subject>Deoxyribonucleic acid</subject><subject>Derivatives</subject><subject>Desensitization, Immunologic - methods</subject><subject>Desensitization, Immunologic - trends</subject><subject>DNA</subject><subject>Experiments</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Humans</subject><subject>Immunopathology</subject><subject>immunotherapy</subject><subject>Medical sciences</subject><subject>Patients</subject><subject>Pollen</subject><subject>Pollen - adverse effects</subject><subject>Pollen - immunology</subject><subject>Quality standards</subject><subject>Recombinant allergens</subject><subject>Recombinant Proteins - genetics</subject><subject>Recombinant Proteins - immunology</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Studies</subject><subject>Vaccines</subject><subject>Vaccines, Synthetic - genetics</subject><subject>Vaccines, Synthetic - immunology</subject><subject>Vaccines, Synthetic - therapeutic use</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kV2r1DAQhoMonvXoH_BCFkS9ap0kTZOACHLwCw4IflyHNJ1oapuuSSvsvzdlFxbOhVdh4HknM88Q8pRCTYG2r4d6sC7UDEDWQGtg4h7ZUdCyahUT98kOQNOqlY2-Io9yHqDUXOmH5IpKzoVS7Y68-opunroQbVz2dhwx_cSY935O-zBNa5yXX5js4fiYPPB2zPjk_F6THx_ef7_5VN1--fj55t1t5ZpWLpXi1gvnfCf6DsFSwKbVrHc9Kqc7wZsOtPfcK88oQ9tKqjvKmpY59EIry6_Jy1PfQ5r_rJgXM4XscBxtxHnNRgIXZXhWwOd3wGFeUyyzGSqgkW3ZsCkUO1EuzTkn9OaQwmTT0VAwm0QzmE2i2SQaoKZILKFn59ZrN2F_iZytFeDFGbDZ2dEnG13IF05JCpyqwr05cViM_Q2YTHYBo8M-JHSL6efw_zne3om7McRQfvyNR8yXfU1mBsy37dzbtUECMN4I_g9p-qNt</recordid><startdate>20070401</startdate><enddate>20070401</enddate><creator>Valenta, Rudolf, MD</creator><creator>Niederberger, Verena, MD</creator><general>Mosby, Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20070401</creationdate><title>Recombinant allergens for immunotherapy</title><author>Valenta, Rudolf, MD ; Niederberger, Verena, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-83af5ccfb5dbe0a10e4692dcde8c9b534b09ff3f8f212ea6719b12462cef598a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Allergens - adverse effects</topic><topic>Allergens - genetics</topic><topic>Allergens - therapeutic use</topic><topic>Allergies</topic><topic>Allergy and Immunology</topic><topic>Animals</topic><topic>Biological activity</topic><topic>Biological and medical sciences</topic><topic>Competition</topic><topic>Deoxyribonucleic acid</topic><topic>Derivatives</topic><topic>Desensitization, Immunologic - methods</topic><topic>Desensitization, Immunologic - trends</topic><topic>DNA</topic><topic>Experiments</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Humans</topic><topic>Immunopathology</topic><topic>immunotherapy</topic><topic>Medical sciences</topic><topic>Patients</topic><topic>Pollen</topic><topic>Pollen - adverse effects</topic><topic>Pollen - immunology</topic><topic>Quality standards</topic><topic>Recombinant allergens</topic><topic>Recombinant Proteins - genetics</topic><topic>Recombinant Proteins - immunology</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Studies</topic><topic>Vaccines</topic><topic>Vaccines, Synthetic - genetics</topic><topic>Vaccines, Synthetic - immunology</topic><topic>Vaccines, Synthetic - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Valenta, Rudolf, MD</creatorcontrib><creatorcontrib>Niederberger, Verena, MD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Valenta, Rudolf, MD</au><au>Niederberger, Verena, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recombinant allergens for immunotherapy</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><addtitle>J Allergy Clin Immunol</addtitle><date>2007-04-01</date><risdate>2007</risdate><volume>119</volume><issue>4</issue><spage>826</spage><epage>830</epage><pages>826-830</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><coden>JACIBY</coden><abstract>Recombinant allergens can be produced as defined molecules in consistent quality and unlimited amounts according to the corresponding DNA template. Furthermore, they can be modified to reduce their allergenic activity and to foster certain advantageous immunologic properties. Recombinant allergens equaling the natural allergens are available for diagnostic and therapeutic purposes, and modified versions have been developed with the aim to to reduce IgE-mediated side effects during immunotherapy. First injection immunotherapy trials conducted with recombinant vaccines for birch pollen and grass pollen allergy show that recombinant allergen–based immunotherapy has vaccination characteristics and is clinically effective. The obtained results hold promise that recombinant allergen–based immunotherapy will improve current immunotherapy practice and may open possibilities for new treatment strategies and possibly even for prophylactic vaccination.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>17335886</pmid><doi>10.1016/j.jaci.2007.01.025</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-6749 |
| ispartof | Journal of allergy and clinical immunology, 2007-04, Vol.119 (4), p.826-830 |
| issn | 0091-6749 1097-6825 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70357332 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); EZB-FREE-00999 freely available EZB journals |
| subjects | Allergens - adverse effects Allergens - genetics Allergens - therapeutic use Allergies Allergy and Immunology Animals Biological activity Biological and medical sciences Competition Deoxyribonucleic acid Derivatives Desensitization, Immunologic - methods Desensitization, Immunologic - trends DNA Experiments Fundamental and applied biological sciences. Psychology Fundamental immunology Humans Immunopathology immunotherapy Medical sciences Patients Pollen Pollen - adverse effects Pollen - immunology Quality standards Recombinant allergens Recombinant Proteins - genetics Recombinant Proteins - immunology Recombinant Proteins - therapeutic use Studies Vaccines Vaccines, Synthetic - genetics Vaccines, Synthetic - immunology Vaccines, Synthetic - therapeutic use |
| title | Recombinant allergens for immunotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T19%3A25%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recombinant%20allergens%20for%20immunotherapy&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Valenta,%20Rudolf,%20MD&rft.date=2007-04-01&rft.volume=119&rft.issue=4&rft.spage=826&rft.epage=830&rft.pages=826-830&rft.issn=0091-6749&rft.eissn=1097-6825&rft.coden=JACIBY&rft_id=info:doi/10.1016/j.jaci.2007.01.025&rft_dat=%3Cproquest_cross%3E3239136001%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1504763354&rft_id=info:pmid/17335886&rft_els_id=S0091674907002345&rfr_iscdi=true |